Journal: Journal of Neuroinflammation

Article Title: Resolvin RvD2 reduces hypothalamic inflammation and rescues mice from diet-induced obesity

doi: 10.1186/s12974-016-0777-2

Figure Lengend Snippet: The hypothalamic expression of proteins involved in the synthesis and action of RvD2. The schematic representation of the main enzymes involved in the synthesis and the receptor for RvD2 ( a ). The transcript expressions of phospholipase A2 ( b ), 15-lipoxigenase ( c ), 5-lipoxigenase ( d ) and GPR18 ( e ) were evaluated using real-time PCR in samples collected from the hypothalamus of mice fed either chow (CT) or a high-fat diet (HF) by the time specified in the graphics ( b – e ). To measure hypothalamic RvD2, we employed a MALDI method, with mass spectra standard of RvD2 corresponding to m/z 375 (( f ), upper panel ); a sample from the hypothalamus of a mice fed on HF (( f ), lower panel ); quantification of RvD2 in hypothalamic samples ( g) . In all experiments, n = 7. In b – e and g , * p < 0.05 vs. respective CT

Article Snippet: The lipid mediator resolvin D2 (sc-351847A) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Techniques: Expressing, Real-time Polymerase Chain Reaction

Journal: Journal of Neuroinflammation

Article Title: Resolvin RvD2 reduces hypothalamic inflammation and rescues mice from diet-induced obesity

doi: 10.1186/s12974-016-0777-2

Figure Lengend Snippet: The impact of dietary substitution of saturated by unsaturated fats on the activity of the RvD2 system in the hypothalamus. Six-week-old Swiss mice were included in the study and fed on chow or HF for 16 weeks. Another group of mice was assigned to HF for 8 weeks following 8 weeks on a HF supplemented with 30% omega 3 (HFS) ( a ). Relative quantification of the RvD2 was made in the hypothalamus of mice fed either chow (CT), the high-fat diet (HF) or the HF supplemented with 30% omega 3 (HFS) ( b ). The transcript expressions of tumour necrosis factor alpha (TNFα) ( c ) and interleukin-1 beta (IL1β) ( d ) were evaluated using real-time PCR in samples collected from the hypothalamus of mice. Caloric intake ( e ) and body mass ( f ) were measured during the experimental period. At the end of the treatment, the experimental groups were subjected to a glucose tolerance test and an insulin tolerance test, and results are shown as the area under the curve (AUC) ( g ) and constant of glucose decay (kITT) ( h ). In all experiments, n = 7. In b – h , * p < 0.05 vs. CT and # p < 0.05 vs. HF

Article Snippet: The lipid mediator resolvin D2 (sc-351847A) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Techniques: Activity Assay, Quantitative Proteomics, Real-time Polymerase Chain Reaction

Journal: Journal of Neuroinflammation

Article Title: Resolvin RvD2 reduces hypothalamic inflammation and rescues mice from diet-induced obesity

doi: 10.1186/s12974-016-0777-2

Figure Lengend Snippet: The impact of DHA-injected icv on the activity of the RvD2 system in the hypothalamus. Six-week-old Swiss mice were included in the study and fed a HF diet for 4 weeks before intracerebroventricular (icv) cannulation; after 1 week, mice were randomly selected for either saline (2 μl) or different amounts of DHA (2 μl) icv treatment for 4 days; some mice were fed on chow throughout the experimental period (CT) ( a ). At the end of the experimental period, hypothalamic RNA was extracted and employed in real-time PCR determinations of phospholipase A2 (PLA2) ( b ), 15-lipoxigenase (15-LOX) ( c ), 5-lipoxigenase (5-LOX) ( d ), GPR18 ( e ), interleukin-6 (IL6) ( f ) and interleukin-10 (IL10) ( g ). Cumulative food intake ( h ) and body mass change ( i ) were evaluated during the experimental period. In all experiments, n = 7. * p < 0.05 vs. CT

Article Snippet: The lipid mediator resolvin D2 (sc-351847A) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Techniques: Injection, Activity Assay, Saline, Real-time Polymerase Chain Reaction

Journal: Journal of Neuroinflammation

Article Title: Resolvin RvD2 reduces hypothalamic inflammation and rescues mice from diet-induced obesity

doi: 10.1186/s12974-016-0777-2

Figure Lengend Snippet: The impact of exogenous RvD2-injected icv on inflammatory and metabolic parameters in mice. Six-week-old Swiss mice were included in the study and fed a HF diet for 8 weeks before intracerebroventricular (icv) cannulation; after 1 week, mice were randomly selected for either saline (2 μl) or different amounts of RvD2 (2, 3 or 50 ng) icv treatment for 11 days ( a ). At the end of the experimental period, hypothalamic RNA was extracted and employed in real-time PCR determinations of GPR18 ( b ). Cumulative food intake ( c ) and body mass variation ( d ) were determined during the experimental period. At the end of the experimental period, the epididymal fat pad was measured ( e ). In addition, mice were submitted a glucose tolerance test, and results are expressed as the area under the curve (AUC) ( f ). Interleukin-6 (IL6) ( g ) and interleukin-10 (IL10) ( h ) transcripts were determined in samples from the hypothalamus, whereas uncoupling protein 1 (UCP1) ( i ) and PGC1a ( j ) transcripts were determined in samples from the brown adipose tissue. Some mice were subjected to indirect calorimetry, resulting in the values for O 2 consumption ( k ), CO 2 production ( l ) and respiratory quotient ( m ). In addition, some mice were subjected to a leptin tolerance test (LTT) and results are expressed as cumulative food intake during 12 h ( n ). In the experiments reported in panels a – j , n = 8; in the experiments reported in panels k – n , n = 5. * p < 0.05 vs. saline. Experiments for evaluation of 3 and 50 ng RvD2 in the hypothalamus were performed in different occasions. The differences obtained in some of the saline groups reflect interexperimental variability. For statistical analysis, group-specific saline control was considered as baseline

Article Snippet: The lipid mediator resolvin D2 (sc-351847A) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Techniques: Injection, Saline, Real-time Polymerase Chain Reaction, Control

Journal: Lipids in Health and Disease

Article Title: Assessment of plasma resolvin levels in women with breast cancer and their associations with disease presentation and immunohistochemical characteristics

doi: 10.1186/s12944-024-02386-5

Figure Lengend Snippet: Differences in plasma resolvin levels between patients with breast cancer and controls. The data revealed higher levels of resolvin D1 in breast cancer patients than in controls ( p = 0.015) (panel A). No differences were observed in resolvin D2, D3 or E1 levels between cancer patients and controls (panel B, C). Data are expressed as pg/ml and are presented as the median (95% CI). * p < 0.05

Article Snippet: All samples were analyzed via the commercially available ELISA kits (Mybiosource, Inc., San Diego, CA, USA): Human Resolvin D1 (RvD1) (Cat. No: MBS053145, sensitivity 5.0 pg/mL); Human Resolvin D2 (RvD2) (Cat. No: MBS051498, sensitivity 5.0 pg/mL); Human Resolvin D3 (RvD3) (Cat. No: MBS056544, sensitivity 2.0 pg/mL); and Resolvin E1 (RvE1) (Cat. No: MBS025958, sensitivity 5.0 pg/mL), in accordance with the manufacturer’s instructions reporting high sensitivity and excellent specificity ( https://www.mybiosource.com ).

Techniques: Clinical Proteomics

Journal: Lipids in Health and Disease

Article Title: Assessment of plasma resolvin levels in women with breast cancer and their associations with disease presentation and immunohistochemical characteristics

doi: 10.1186/s12944-024-02386-5

Figure Lengend Snippet: Linear correlations between plasma resolvin levels in breast cancer patients

Article Snippet: All samples were analyzed via the commercially available ELISA kits (Mybiosource, Inc., San Diego, CA, USA): Human Resolvin D1 (RvD1) (Cat. No: MBS053145, sensitivity 5.0 pg/mL); Human Resolvin D2 (RvD2) (Cat. No: MBS051498, sensitivity 5.0 pg/mL); Human Resolvin D3 (RvD3) (Cat. No: MBS056544, sensitivity 2.0 pg/mL); and Resolvin E1 (RvE1) (Cat. No: MBS025958, sensitivity 5.0 pg/mL), in accordance with the manufacturer’s instructions reporting high sensitivity and excellent specificity ( https://www.mybiosource.com ).

Techniques: Clinical Proteomics

Journal: Lipids in Health and Disease

Article Title: Assessment of plasma resolvin levels in women with breast cancer and their associations with disease presentation and immunohistochemical characteristics

doi: 10.1186/s12944-024-02386-5

Figure Lengend Snippet: Differences in plasma resolvin levels in the cancer group according to the form of presentation (sporadic, familiar and BRCA1/2 mutated groups). The data revealed lower levels of resolvin D1 in BRCA1/2-mutated patients than in the familiar and sporadic patients ( p = 0.031 and p = 0.020, respectively) (panel A). The data revealed lower levels of resolvin D3 in BRCA1/2-mutated patients than in the familiar and sporadic patients ( p = 0.031 and p = 0.013, respectively) (panel C). No difference was observed in the resolvins D2 and E1 levels among the three groups (panel B, D). Data are expressed as pg/ml and are presented as the median (95% CI). * p < 0.05

Article Snippet: All samples were analyzed via the commercially available ELISA kits (Mybiosource, Inc., San Diego, CA, USA): Human Resolvin D1 (RvD1) (Cat. No: MBS053145, sensitivity 5.0 pg/mL); Human Resolvin D2 (RvD2) (Cat. No: MBS051498, sensitivity 5.0 pg/mL); Human Resolvin D3 (RvD3) (Cat. No: MBS056544, sensitivity 2.0 pg/mL); and Resolvin E1 (RvE1) (Cat. No: MBS025958, sensitivity 5.0 pg/mL), in accordance with the manufacturer’s instructions reporting high sensitivity and excellent specificity ( https://www.mybiosource.com ).

Techniques: Clinical Proteomics

Journal: Lipids in Health and Disease

Article Title: Assessment of plasma resolvin levels in women with breast cancer and their associations with disease presentation and immunohistochemical characteristics

doi: 10.1186/s12944-024-02386-5

Figure Lengend Snippet: Differences in plasma resolvin levels between the sporadic plus familiar group and the BRCA1/2 mutated patient group. The data revealed lower levels of resolvin D1 and resolvin D3 in BRCA1/2-mutated patients than in the familiar plus sporadic patients ( p = 0.014 and p = 0.010, respectively) (panels A, C). Resolvin D2 and E1 levels tended to be lower in the BRCA1/2-mutated group than in the sporadic plus familiar group ( p = 0.051 and p = 0.062, respectively). Data are expressed as pg/ml and are presented as the median (95% CI). * p < 0.05

Article Snippet: All samples were analyzed via the commercially available ELISA kits (Mybiosource, Inc., San Diego, CA, USA): Human Resolvin D1 (RvD1) (Cat. No: MBS053145, sensitivity 5.0 pg/mL); Human Resolvin D2 (RvD2) (Cat. No: MBS051498, sensitivity 5.0 pg/mL); Human Resolvin D3 (RvD3) (Cat. No: MBS056544, sensitivity 2.0 pg/mL); and Resolvin E1 (RvE1) (Cat. No: MBS025958, sensitivity 5.0 pg/mL), in accordance with the manufacturer’s instructions reporting high sensitivity and excellent specificity ( https://www.mybiosource.com ).

Techniques: Clinical Proteomics

Journal: Lipids in Health and Disease

Article Title: Assessment of plasma resolvin levels in women with breast cancer and their associations with disease presentation and immunohistochemical characteristics

doi: 10.1186/s12944-024-02386-5

Figure Lengend Snippet: Differences in plasma resolvin D1 levels between triple-negative and nontriple-negative breast cancer patients. The data revealed lower levels of resolvin D1 in triple-negative patients than in non-triple-negative patients ( p = 0.023). Data are expressed as pg/ml and are presented as the median (95% CI). * p < 0.05

Article Snippet: All samples were analyzed via the commercially available ELISA kits (Mybiosource, Inc., San Diego, CA, USA): Human Resolvin D1 (RvD1) (Cat. No: MBS053145, sensitivity 5.0 pg/mL); Human Resolvin D2 (RvD2) (Cat. No: MBS051498, sensitivity 5.0 pg/mL); Human Resolvin D3 (RvD3) (Cat. No: MBS056544, sensitivity 2.0 pg/mL); and Resolvin E1 (RvE1) (Cat. No: MBS025958, sensitivity 5.0 pg/mL), in accordance with the manufacturer’s instructions reporting high sensitivity and excellent specificity ( https://www.mybiosource.com ).

Techniques: Clinical Proteomics

Journal: Lipids in Health and Disease

Article Title: Assessment of plasma resolvin levels in women with breast cancer and their associations with disease presentation and immunohistochemical characteristics

doi: 10.1186/s12944-024-02386-5

Figure Lengend Snippet: Differences in plasma resolvin D3 levels according to Ki-67% expression. The data revealed lower levels of resolvin D3 in breast cancer patients with high Ki-67 expression (≥ 20%) than in those with low Ki-67 expression ( p = 0.034). Data are expressed as pg/ml and are presented as the median (95% CI). * p < 0.05

Article Snippet: All samples were analyzed via the commercially available ELISA kits (Mybiosource, Inc., San Diego, CA, USA): Human Resolvin D1 (RvD1) (Cat. No: MBS053145, sensitivity 5.0 pg/mL); Human Resolvin D2 (RvD2) (Cat. No: MBS051498, sensitivity 5.0 pg/mL); Human Resolvin D3 (RvD3) (Cat. No: MBS056544, sensitivity 2.0 pg/mL); and Resolvin E1 (RvE1) (Cat. No: MBS025958, sensitivity 5.0 pg/mL), in accordance with the manufacturer’s instructions reporting high sensitivity and excellent specificity ( https://www.mybiosource.com ).

Techniques: Clinical Proteomics, Expressing